These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 32442469)
1. Cathelicidin represents a new target for manipulation of skin inflammation in Netherton syndrome. Zingkou E; Pampalakis G; Sotiropoulou G Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165831. PubMed ID: 32442469 [TBL] [Abstract][Full Text] [Related]
2. A proinflammatory role of KLK6 protease in Netherton syndrome. Zingkou E; Pampalakis G; Charla E; Nauroy P; Kiritsi D; Sotiropoulou G J Dermatol Sci; 2019 Jul; 95(1):28-35. PubMed ID: 31255470 [TBL] [Abstract][Full Text] [Related]
3. KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome. Furio L; Pampalakis G; Michael IP; Nagy A; Sotiropoulou G; Hovnanian A PLoS Genet; 2015 Sep; 11(9):e1005389. PubMed ID: 26390218 [TBL] [Abstract][Full Text] [Related]
4. Cocktails of KLK5 Protease Inhibitors and Anti-TNFα Therapeutics: an Effective Treatment for Netherton Syndrome. Zingkou E; Pampalakis G; Sotiropoulou G J Clin Immunol; 2022 Apr; 42(3):597-605. PubMed ID: 35040012 [TBL] [Abstract][Full Text] [Related]
5. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7. Wang S; Olt S; Schoefmann N; Stuetz A; Winiski A; Wolff-Winiski B Exp Dermatol; 2014 Jul; 23(7):524-6. PubMed ID: 24848304 [TBL] [Abstract][Full Text] [Related]
7. Dual antibody inhibition of KLK5 and KLK7 for Netherton syndrome and atopic dermatitis. Chavarria-Smith J; Chiu CPC; Jackman JK; Yin J; Zhang J; Hackney JA; Lin WY; Tyagi T; Sun Y; Tao J; Dunlap D; Morton WD; Ghodge SV; Maun HR; Li H; Hernandez-Barry H; Loyet KM; Chen E; Liu J; Tam C; Yaspan BL; Cai H; Balazs M; Arron JR; Li J; Wittwer AJ; Pappu R; Austin CD; Lee WP; Lazarus RA; Sudhamsu J; Koerber JT; Yi T Sci Transl Med; 2022 Dec; 14(675):eabp9159. PubMed ID: 36516271 [TBL] [Abstract][Full Text] [Related]
8. Genetic activation of Nrf2 reduces cutaneous symptoms in a murine model of Netherton syndrome. Muzumdar S; Koch M; Hiebert H; Bapst A; Gravina A; Bloch W; Beer HD; Werner S; Schäfer M Dis Model Mech; 2020 Jun; 13(5):. PubMed ID: 32457102 [TBL] [Abstract][Full Text] [Related]
9. Transgenic Kallikrein 14 Mice Display Major Hair Shaft Defects Associated with Desmoglein 3 and 4 Degradation, Abnormal Epidermal Differentiation, and IL-36 Signature. Gouin O; Barbieux C; Leturcq F; Bonnet des Claustres M; Petrova E; Hovnanian A J Invest Dermatol; 2020 Jun; 140(6):1184-1194. PubMed ID: 32169475 [TBL] [Abstract][Full Text] [Related]
10. Establishment of a mouse model of Netherton syndrome based on CRISPR/Cas9 technology. Guo JZ; Su J; Dai H; Wang XY; Wu WB; Chen T; Zhang J; Wang WH Eur J Dermatol; 2022 Jul; 32(4):459-463. PubMed ID: 36301754 [TBL] [Abstract][Full Text] [Related]
11. Physiological and pathological roles of kallikrein-related peptidases in the epidermis. Kishibe M J Dermatol Sci; 2019 Aug; 95(2):50-55. PubMed ID: 31279501 [TBL] [Abstract][Full Text] [Related]
12. Generation and Clinical Application of Gene-Modified Autologous Epidermal Sheets in Netherton Syndrome: Lessons Learned from a Phase 1 Trial. Di WL; Lwin SM; Petrova A; Bernadis C; Syed F; Farzaneh F; Moulding D; Martinez AE; Sebire NJ; Rampling D; Virasami A; Zamiri M; Wang W; Hara H; Kadiyirire T; Abdul-Wahab A; Martinez-Queipo M; Harper JI; McGrath JA; Thrasher AJ; Mellerio JE; Qasim W Hum Gene Ther; 2019 Sep; 30(9):1067-1078. PubMed ID: 31288584 [TBL] [Abstract][Full Text] [Related]
13. Toll-like receptor signaling induces the expression of lympho-epithelial Kazal-type inhibitor in epidermal keratinocytes. Sugimoto S; Morizane S; Nomura H; Kobashi M; Sugihara S; Iwatsuki K J Dermatol Sci; 2018 Nov; 92(2):181-187. PubMed ID: 30270115 [TBL] [Abstract][Full Text] [Related]
14. Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model. Briot A; Lacroix M; Robin A; Steinhoff M; Deraison C; Hovnanian A J Invest Dermatol; 2010 Dec; 130(12):2736-42. PubMed ID: 20703245 [TBL] [Abstract][Full Text] [Related]
15. A novel SPINK5 donor splice site variant in a child with Netherton syndrome. Mintoff D; Borg I; Vornweg J; Mercieca L; Merdzanic R; Numrich J; Aquilina S; Pace NP; Fischer J Mol Genet Genomic Med; 2021 Mar; 9(3):e1611. PubMed ID: 33534181 [TBL] [Abstract][Full Text] [Related]
16. LEKTI domains D6, D7 and D8+9 serve as substrates for transglutaminase 1: implications for targeted therapy of Netherton syndrome. Wiegmann H; Valentin F; Tarinski T; Liebau E; Loser K; Traupe H; Oji V Br J Dermatol; 2019 Nov; 181(5):999-1008. PubMed ID: 30801672 [TBL] [Abstract][Full Text] [Related]
17. Comparative analyses of Netherton syndrome patients and Spink5 conditional knock-out mice uncover disease-relevant pathways. Petrova E; López-Gay JM; Fahrner M; Leturcq F; de Villartay JP; Barbieux C; Gonschorek P; Tsoi LC; Gudjonsson JE; Schilling O; Hovnanian A Commun Biol; 2024 Feb; 7(1):152. PubMed ID: 38316920 [TBL] [Abstract][Full Text] [Related]
18. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. Briot A; Deraison C; Lacroix M; Bonnart C; Robin A; Besson C; Dubus P; Hovnanian A J Exp Med; 2009 May; 206(5):1135-47. PubMed ID: 19414552 [TBL] [Abstract][Full Text] [Related]
19. Netherton syndrome previously misdiagnosed as hyper IgE syndrome caused by a probable mutation in SPINK5 C. Özyurt K; Atasoy M; Ertaş R; Ulaş Y; Akkuş MR; Kiraz A; Hennies HC Turk J Pediatr; 2019; 61(4):604-607. PubMed ID: 31990481 [TBL] [Abstract][Full Text] [Related]
20. Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome. Furio L; de Veer S; Jaillet M; Briot A; Robin A; Deraison C; Hovnanian A J Exp Med; 2014 Mar; 211(3):499-513. PubMed ID: 24534191 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]